AltheaDx focuses on assisting physicians, managed care organizations, pharmaceutical companies and other healthcare entities in their efforts to make the best possible therapeutic decisions for patients through the implementation of personalized medicine. We are dedicated to building trust and loyalty from our customers by providing accurate and timely laboratory results while proactively offering superior service and the most innovative products in the industry.
AltheaDx, Inc. is a commercial stage molecular diagnostics company specializing in the field of pharmacogenomics (PGx). We were incorporated in 2013 as a spin out from Althea, Inc. after a $175m acquisition by Ajinomoto. We are a private company based in San Diego, California and aim to help healthcare providers better prescribe treatment medications. With an experienced team in place, we maintain a CAP-Accredited, CLIA-Certified laboratory (State of California), which is also approved by the New York State Department of Health
NeuroIDgenetix is our flagship PGx product test for depression and anxiety and is supported by a successful and published/peer-reviewed Randomized Controlled Trial. This trial demonstrated clinical utility over standard of care when physicians used our test prior to prescribing a medication. NeuroIDgenetix for depression and anxiety is designed to enable healthcare providers to make timely and evidence-based decisions, which we believe can reduce the overall cost of patient care by reducing adverse events, optimizing patients’ overall therapeutic regimen and helping to achieve a faster therapeutic response. According to the Centers for Disease Control, 4.7% of adults over the age of 18 have regular feelings of depression. Additionally, 9.3% of physician office visits have depression indicated on the medical record, and 9.4% of all emergency department visits have depression indicated on the medical record. NeuroIDgenetix for depression is reimbursed by Medicare since the fall of 2020.
We also have a development portfolio supported by smaller clinical studies which will enable personalized therapeutic decisions for patients suffering from some of the most prevalent clinical conditions in the United States, including: cardiovascular disease, neuropsychiatric disorders and pain. Our bioinformatics platform and PGx product testing portfolio are intended to serve as tools to assist healthcare providers in identifying optimal drugs for their patients, as well as dosing guidelines based on a patient’s genetic make-up, current prescription regimen and other key factors.
We believe that without prior knowledge of an individual patient’s genetic profile there are significant health concerns and unnecessary costs associated with the trial-and-error manner by which many physicians prescribe drugs. There are an estimated 100,000 deaths and more than two million serious adverse reactions attributable to prescription drug use in the United States each year, at a cost to the healthcare industry that exceeds $136 billion annually. It has been estimated that genetics can account for up to 95% of variability in drug disposition and effect, and as much as 40-60% of adverse drug reactions. We believe IDgenetix can improve clinical outcomes and reduce the overall cost of prescription drugs by enabling better drug selection, earlier favorable results and lower occurrence of adverse events.
Our current offering is NeuroIDgenetix and we are designing IDgenetix to provide a comprehensive PGx test offering to best meet the future needs of our target customers such as: long-term and post-acute care facilities, government facilities, integrated delivery networks, or IDNs, and managed care organizations. These institutional healthcare providers require broad PGx testing capabilities to manage a large and diverse patient population, with patients often suffering from multiple clinical conditions. These customers often operate under fixed-fee-per-patient or fixed-fee-per-procedure arrangements and are searching for ways to improve clinical outcomes at the lowest possible cost. In addition, all our current and future test address/will address the needs of physicians across multiple specialties, such as cardiologists, general practitioners, obstetricians and neurologists.